Oral Administration of 24,25(OH)2D3 Suppresses the Serum Parathyroid Hormone Levels of Dialysis Patients
| Autor: | Ben-Ezer D, Conforty A, Bdolah-Abram T, Shraga Shany, Kafka Dr, Cidio Chaimovitz, Jayson Rapoport, Edelstein S |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
medicine.medical_specialty
Hyperparathyroidism Calcitriol business.industry Continuous ambulatory peritoneal dialysis Parathyroid hormone chemistry.chemical_element Calcium medicine.disease End stage renal disease Endocrinology chemistry Oral administration Internal medicine medicine Secondary hyperparathyroidism business medicine.drug |
| Zdroj: | Nephron. 58:283-287 |
| ISSN: | 2235-3186 1660-8151 |
| DOI: | 10.1159/000186437 |
| Popis: | We measured the serum parathyroid hormone (PTH) levels in 20 patients treated with continuous ambulatory peritoneal dialysis before and after oral treatment with 24,25-dihydroxyvitamin D3- 24,25(OH)2D3. This metabolite was given in addition to existing treatment with 1α-OH-D3 and calcium carbonate. Administration of 24,25(OH)2D3 led to a significant decrease in PTH levels (intact molecule) from 382 ± (SE) 65 to 245 ± 54 pg/ml in 9 patients whose initial levels were extremely high (p = 0.01). No side effects were observed. On the average, calcium values were unchanged and within the normal range throughout the study period; however, a few episodes of mild asymptomatic hypercalcemia occurred which responded quickly to reduction of the calcium carbonate dosage. The present study suggests that oral administration of 24,25(OH)2D3 combined with 1α-OH-D3 is safe and capable of suppressing the raised serum PTH levels of end-stage renal disease patients without the danger of significant hypercalcemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|